EUCTR2005-003129-23-GB进行中(未招募)1 期
Prevention and Treatment of Steroid-Induced Osteopenia in children and adolescents with rheumatic diseases - POPS
Belfast Health and Social Care Trust, Musgrave Park Hospital0 个研究点目标入组 216 人开始时间: 2006年2月24日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Children and adolescents between the ages of 4 and 18 with a definite diagnosis of JIA, JDM, JSLE and vasculitis who are commencing or are receiving corticosteroids. This is the typical patient group who will receive corticosteroids for these diseases and experience steroid induced osteopenia
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 216
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Children who are commencing steroids but where the duration of steroid treatment is expected to be less than 3 months (i.e. short term) should not be recruited.
- •Co-morbid conditions known to be associated with osteopaenia:
- •Cystic fibrosis, malabsorption, severe renal disease, severe asthma, cancer, osteogenesis imperfecta, inflammatory bowel disease.
- •Have a history of using any bisphosphonate (except for more than a single dose of Risedronate) and/or fluoride (>10 mg per day).
- •Have a history of cancer.
- •Have untreated rickets within one year prior to enrollment.
- •Evidence of clinically significant organic or psychiatric disease on history or physical examination which in the opinion of the investigator would prevent the patient from completing the study.
- •Have markedly abnormal pretreatment laboratory findings, except if in the opinion of the investigator, it would not prevent the patient from completing the study.
- •Have a history of using anabolic steroids/estrogens/androgens within one year of enrollment.
- •Have a documented history of an abnormal or allergic reaction to bisphosphonates.
- •Pregnancy or sexually active subjects unwilling to take appropriate contraceptive measures.
- •Any limb-lengthening procedure within 6 months of enrollment.
研究者
相似试验
已完成
不适用
Steroid induced osteopaenia: prophylaxis and treatment in paediatric rheumatic diseasesJuvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Juvenile Systemic Lupus Erythematosus (JSLE)Musculoskeletal DiseasesOther systemic involvement of connective tissueISRCTN66814619Greenpark Healthcare Trust (UK)300
尚未招募
不适用
Treatment strategies for Medication-related osteonecrosis of the jaw - a prospective, partially randomized patient preference trialMedication-related osteonecrosis of the jawM87.18DRKS00012888Klinik und Poliklinik für Mund-, Kiefer- & Gesichtschirurgie, Universitätsklinikum Heidelberg, Ärztlicher Direktor: Prof. Dr. Dr. Jürgen Hoffmann90
进行中(未招募)
1 期
STEPS-EA trialStrictures after esophageal atresia repairCTIS2023-504905-36-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)110
招募中
不适用
Intralesional Steroid Injections to Prevent Refractory Strictures in Patients with Esophageal Atresia – a randomized controlled trial (STEPS-EA)NL-OMON26384Erasmus MC - Sophia Children's Hospital110
已完成
不适用
Efficacy of steroid therapy for prevention of recurrent cerebral amyloid angiopathy-related hemorrhage.Cerebral amyloid angiopathyJPRN-UMIN000011623Aizawa Hospital20
